USA flag logo/image

An Official Website of the United States Government

Apyrase to treat ischemia/reperfusion injury during lung transplantation

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85809
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
HL087456
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
APT THERAPEUTICS, INC.
4041 Forest Park Avenue SAINT LOUIS, MO -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: Apyrase to treat ischemia/reperfusion injury during lung transplantation
Agency: HHS
Contract: 2R44HL087456-02
Award Amount: $839,863.00
 

Abstract:

DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy to prevent or reduce ischemia-reperfusion injury during lung transplantation. The enzyme strongly preserves vascular integrity and inhibits platelet activation and agg regation without increasing bleeding risk. Using a protein informatics approach, we have successfully engineered an optimized human apyrase, APT102. With Phase II grant support, We will determine whether APT102 improves lung allograft function without incr easing bleeding risk in clinically relevant models of allogeneic orthotopic lung transplantation in rats and dogs. The ultimate goal is to demonstrate whether APT102 has the potential to be a therapy for transplantation-associated and other vascular diseas es. PUBLIC HEALTH RELEVANCE: We will determine whether human apyrase improves lung allograft function without increasing bleeding risk in clinically relevant models of allogeneic orthotopic lung transplantation in rats and dogs.

Principal Investigator:

Ridong Chen
3146086932
RCHEN@NIDUSCENTER.COM

Business Contact:

Ridong Chen
rchen@niduscenter.com
Small Business Information at Submission:

APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC. 893 NORTH WARSON ROAD SAINT LOUIS, MO 63141

EIN/Tax ID: 431947715
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No